Rakesh Jain, MD, MPH

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

Can methylfolate play a role in the adjunctive treatment of patients with major depression? In this podcast, Rakesh Jain, MD, offers insights.

What the New Mind-Body Science Tells Us About the Pathophysiology of Major Depression-Focus on Treatment

As we begin this brief review of the neurobiology of major depressive disorder (MDD), we face these fundamental questions

We would suggest that psychiatry has spent so many years taking its diagnostic categories as God-given that it has become inured to the fact that these categories tell us very little about the etiology and fundamental nature of the conditions they purport to encompass.

Lecturing around the country has left us with the powerful impression that both psychiatrists and primary care physicians are hungry for new ways to think about and manage depression and the myriad symptoms and syndromes with which it is associated-including attention deficit disorder, insomnia, chronic pain conditions, substance abuse, and various states of disabling anxiety.

Lecturing around the country has left us with the powerful impression that both psychiatrists and primary care physicians are hungry for new ways to think about and treat depression and the myriad symptoms and syndromes with which it is associated-including attention deficit disorder, insomnia, chronic pain conditions, substance abuse, and various states of disabling anxiety. Primary care physicians also seem especially excited to learn that depression is not just a psychiatric illness but a behavioral manifestation of underlying pathophysiological processes that promote most of the other conditions they struggle to treat-including cardiovascular disease, diabetes, cancer, and dementia.1,2